Literature DB >> 11753046

Hepatic resection for metastatic tumors from gastric cancer.

Keiichi Okano1, Takashi Maeba, Ken Ishimura, Yukihiko Karasawa, Fuminori Goda, Hisao Wakabayashi, Hisashi Usuki, Hajime Maeta.   

Abstract

OBJECTIVE: To assess the surgical results and clinicopathologic features of hepatic metastases from gastric adenocarcinoma to identify patients with a better probability of survival. SUMMARY BACKGROUND DATA: Many studies have reported the benefit of hepatic resection for metastatic tumors from colorectal cancer. However, indications for a surgical approach for gastric adenocarcinoma involving the liver have not been clearly defined.
METHODS: Ninety (11%) of 807 patients with primary gastric cancer were diagnosed with synchronous (n = 78) or metachronous (n = 12) hepatic metastases. Of these, 19 underwent 20 resections intended to cure the metastatic lesion in the liver. The clinicopathologic features of the hepatic metastases in, and the surgical results for, the 19 patients were analyzed.
RESULTS: The actuarial 1-year, 3-year, and 5-year survival rates after hepatic resection were, respectively, 77%, 34%, and 34%, and three patients survived for more than 5 years after surgery. Solitary and metachronous metastases were significant determinants for a favorable prognosis after hepatic resection. Pathologically, a fibrous pseudocapsule between the tumor and surrounding hepatic parenchyma was found in 13 of the 19 patients (68%). The presence of a peritumoral fibrous pseudocapsule and a well-differentiated histologic type of metastatic nodule were significant prognostic factors. Factors associated with the primary lesion were not significant prognostic determinants in patients who underwent curative resection of the primary cancer.
CONCLUSIONS: Solitary and metachronous metastases from gastric cancer should be treated by a surgical approach and confer a better prognosis. A new prognostic factor, the presence of a pseudocapsule, may be helpful in defining indications for postoperative adjuvant treatment.

Entities:  

Mesh:

Year:  2002        PMID: 11753046      PMCID: PMC1422399          DOI: 10.1097/00000658-200201000-00011

Source DB:  PubMed          Journal:  Ann Surg        ISSN: 0003-4932            Impact factor:   12.969


  24 in total

1.  Technical and biological factors in disease-free survival after hepatic resection for colorectal cancer metastases.

Authors:  B Cady; M D Stone; W V McDermott; R L Jenkins; A Bothe; P T Lavin; E J Lovett; G D Steele
Journal:  Arch Surg       Date:  1992-05

2.  Hepatic metastases from colorectal carcinoma: impact of surgical resection on the natural history.

Authors:  J Scheele; R Stangl; A Altendorf-Hofmann
Journal:  Br J Surg       Date:  1990-11       Impact factor: 6.939

3.  Macroscopic intrabiliary growth of liver metastases from colorectal cancer.

Authors:  K Okano; J Yamamoto; Y Moriya; T Akasu; T Kosuge; M Sakamoto; S Hirohashi
Journal:  Surgery       Date:  1999-11       Impact factor: 3.982

4.  Fibrous pseudocapsule of metastatic liver tumors from colorectal carcinoma. Clinicopathologic study of 152 first resection cases.

Authors:  K Okano; J Yamamoto; T Kosuge; S Yamamoto; M Sakamoto; Y Nakanishi; S Hirohashi
Journal:  Cancer       Date:  2000-07-15       Impact factor: 6.860

5.  Clinical evaluation of hepatic arterial infusion of low dose-CDDP and 5-FU with hyperthermotherapy: a preliminary study for liver metastases from esophageal and gastric cancer.

Authors:  M Iwahashi; H Tanimura; M Nakamori; Y Nagai; N Hirabayashi; K Ueda; K Matsuda; T Tsunoda; H Yamaue
Journal:  Hepatogastroenterology       Date:  1999 Jul-Aug

6.  Synchronous, metachronous, and multiple hepatic resections of liver tumors originating from primary gastric tumors.

Authors:  S D Bines; G England; D J Deziel; T R Witt; A Doolas; D L Roseman
Journal:  Surgery       Date:  1993-10       Impact factor: 3.982

Review 7.  Resection of the liver for colorectal carcinoma metastases: a multi-institutional study of indications for resection. Registry of Hepatic Metastases.

Authors: 
Journal:  Surgery       Date:  1988-03       Impact factor: 3.982

8.  Effect of intra-hepatoarterial infusion of MMC and CDDP for gastric cancer patients with liver metastases.

Authors:  Y Yonemura; N Matuki; H Sakuma; K Katayama; T Sawa; T Fujimura; S Ohyama; K Miwa; I Miyazaki; M Tanaka
Journal:  Surg Today       Date:  1992       Impact factor: 2.549

9.  Pertinent risk factors and gastric carcinoma with synchronous peritoneal dissemination or liver metastasis.

Authors:  Y Maehara; S Moriguchi; Y Kakeji; S Kohnoe; D Korenaga; M Haraguchi; K Sugimachi
Journal:  Surgery       Date:  1991-11       Impact factor: 3.982

10.  Evaluation of treatment for gastric cancer with liver metastasis.

Authors:  K Okuyama; K Isono; I K Juan; S Onoda; T Ochiai; Y Yamamoto; Y Koide; H Satoh
Journal:  Cancer       Date:  1985-05-15       Impact factor: 6.860

View more
  81 in total

Review 1.  Liver resections in metastatic gastric cancer.

Authors:  Sid P Kerkar; Clinton D Kemp; Itzhak Avital
Journal:  HPB (Oxford)       Date:  2010-11       Impact factor: 3.647

Review 2.  Modern imaging techniques for preoperative detection of distant metastases in gastric cancer.

Authors:  Robert M Kwee; Thomas C Kwee
Journal:  World J Gastroenterol       Date:  2015-10-07       Impact factor: 5.742

Review 3.  Surgical resection of hepatic metastasis from gastric cancer: a review and new recommendation in the Japanese gastric cancer treatment guidelines.

Authors:  Yasuhiro Kodera; Kazumasa Fujitani; Norimasa Fukushima; Seiji Ito; Kei Muro; Norifumi Ohashi; Takaki Yoshikawa; Daisuke Kobayashi; Chie Tanaka; Michitaka Fujiwara
Journal:  Gastric Cancer       Date:  2014-04       Impact factor: 7.370

4.  Response to preoperative chemotherapy predicts survival in patients undergoing hepatectomy for liver metastases from gastric and esophageal cancer.

Authors:  Andreas Andreou; Luca Viganò; Giuseppe Zimmitti; Daniel Seehofer; Martin Dreyer; Andreas Pascher; Marcus Bahra; Wenzel Schoening; Volker Schmitz; Peter C Thuss-Patience; Timm Denecke; Gero Puhl; Jean-Nicolas Vauthey; Peter Neuhaus; Lorenzo Capussotti; Johann Pratschke; Sven-Christian Schmidt
Journal:  J Gastrointest Surg       Date:  2014-08-27       Impact factor: 3.452

Review 5.  Strategies for treating liver metastasis from gastric cancer.

Authors:  Yoshihiro Kakeji; Masaru Morita; Yoshihiko Maehara
Journal:  Surg Today       Date:  2010-03-26       Impact factor: 2.549

6.  Reported outcome factors for hepatic metastasectomy.

Authors:  N Joseph Espat
Journal:  J Gastrointest Surg       Date:  2006-02       Impact factor: 3.452

Review 7.  The role of surgery in the therapeutic approach of gastric cancer liver metastases.

Authors:  Aikaterini Mastoraki; Christina Benetou; Sotiria Mastoraki; Ioannis S Papanikolaou; Nikolaos Danias; Vassilios Smyrniotis; Nikolaos Arkadopoulos
Journal:  Indian J Gastroenterol       Date:  2016-08-16

8.  Improving perioperative outcome expands the role of hepatectomy in management of benign and malignant hepatobiliary diseases: analysis of 1222 consecutive patients from a prospective database.

Authors:  Ronnie T Poon; Sheung Tat Fan; Chung Mau Lo; Chi Leung Liu; Chi Ming Lam; Wai Key Yuen; Chun Yeung; John Wong
Journal:  Ann Surg       Date:  2004-10       Impact factor: 12.969

9.  Long-term survival after surgical resection for liver metastasis from gastric cancer: two case reports.

Authors:  Jong Keun Lim; Joong Bae Ahn; Sung Ha Cheon; Hyun Chang; Jong Yul Jung; Sun Young Rha; Jae Kyung Roh; Sung Hoon Noh; Ho Geun Kim; Hyun Cheol Chung; Hei-Cheul Jeung
Journal:  Cancer Res Treat       Date:  2006-06-30       Impact factor: 4.679

10.  High survival in patients operated for small isolated liver metastases from gastric cancer: a multi-institutional study.

Authors:  Koji Komeda; Michihiro Hayashi; Shoji Kubo; Hiroaki Nagano; Takuya Nakai; Masaki Kaibori; Hiroshi Wada; Shigekazu Takemura; Masahiko Kinoshita; Chikato Koga; Masataka Matsumoto; Tatsuma Sakaguchi; Yoshihiro Inoue; Fumitoshi Hirokawa; A-Hon Kwon; Kazuhisa Uchiyama
Journal:  World J Surg       Date:  2014-10       Impact factor: 3.352

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.